Cullinan Therapeutics (CGEM) is a pre-revenue clinical-stage biopharmaceutical company with a balance sheet dominated by liquid financial assets and minimal hard assets. As of March 31, 2026, total assets were $403.0M against total liabilities of $36.8M, yielding GAAP book equity of $366.2M. Under liquidation lens, the asset side haircuts are minimal given the composition: cash and cash equivalents of $75.1M recover at 100%; short-term marketable securities of $276.8M (predominantly investment-grade debt securities per the filing's fair value hierarchy disclosures, amortized cost $315.2M with net unrealized gain of $127K) recover at effectively par or near-par; long-term investments of $38.5M similarly are investment securities recovering close to carrying value. Prepaid expenses of $9.5M are largely non-recoverable on liquidation (0-10% recovery). PP&E net of $342K is de minimis. Right-of-use asset of $2.4M carries a matching operating lease liability of $2.4M — these offset. Intangibles carried at zero on the balance sheet (all R&D expensed as incurred); in-process R&D and pipeline have no balance sheet value and contribute nothing to liquidation recovery under this lens. On the liability side, total liabilities of $36.8M include accrued liabilities of $31.9M (current), accounts payable of $2.5M, operating lease obligations of $2.4M, and other current liabilities of $1.4M. All liabilities settle at face value. Estimated liquidation recovery to equity: approximately $75M (cash, 100%) + $315M (marketable securities, ~100% given investment-grade short duration) + $38.5M (long-term securities, ~100%) minus ~$9.5M prepaid haircut (assume 0% recovery) minus total liabilities of $36.8M = roughly $383M gross liquid assets less $36.8M liabilities = approximately $346M net recovery to equity. This compares to MFFAIS CLV/LLV/OLV of $38.3M — that figure appears materially understated relative to the filing data and may reflect a stale or miscalculated input. The accumulated deficit stands at $637.8M. Cash burn for Q1 2026 was $46.0M operating outflow. At this rate, roughly 7-8 quarters of runway from the $393M in total investments and cash reported. Post-period, in April 2026 the company established a $200M ATM facility with TD Cowen, which does not affect the March 31 balance sheet but represents a potential future dilutive equity source. Two programs (CLN-617, CLN-619) were discontinued in late 2025, reducing forward burn somewhat. The filing does not separately tag the ATM facility capacity or off-balance-sheet milestone payment obligations (up to $130M in Taiho regulatory milestones eligible to receive, and contingent milestone payment obligations to licensors) in XBRL.
▼ Community Notes